Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of OMS906 in healthy volunteers
NL-OMON49225Phase 1Withdrawn
- Sponsor
- Omeros Corporation
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) (10 cohorts), sponsored by Omeros Corporation. Primary endpoints: Safety and tolerability after single ascending doses and Safety and tolerability after multiple ascending doses. Planned start Jul 2020; status: withdrawn.
02
Drugs
zaltenibart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON49225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49225.